GUGGENHIME ANDREW 4

What Happened

• Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte (PCVX), surrendered 1,021 shares at $59.32 per share (total value $60,566) on March 9, 2026 to satisfy tax withholding obligations related to vested restricted stock units (RSUs). This was a tax-withholding share surrender (Form 4 code F), not an open-market sale.

Key Details

• Transaction date and price: March 9, 2026 — 1,021 shares at $59.32 each (total $60,566).
• Transaction type/code: Tax withholding upon vesting (code F) — shares were surrendered to the issuer to cover withholding.
• Shares owned after transaction: Not specified in this filing.
• Footnotes:
  • F1: Shares were surrendered to cover applicable tax withholding from RSU vesting; no other shares subject to the January 29, 2026 lock-up were sold by the reporting person.
  • F2: Some shares are held by ALG 2025 GRAT HOLDINGS LLC, owned by a grantor retained annuity trust for which Guggenhime is annuitant and trustee.
• Filing timeliness: Reported on March 11, 2026 (filed within the typical Form 4 deadline).

Context

• This was a routine "sell-to-cover"/share surrender to pay taxes on vested RSUs, which is common and does not necessarily signal a view on the company’s stock. It differs from an open-market sale because the shares were transferred to the issuer for tax purposes rather than sold to other investors.